CERT stock news today

Certara named a leader in AI predictive toxicology market

Certara has been identified as a leader in the market for AI-powered predictive toxicology. The recognition highlights its position in this area of drug safety testing.

KeyBanc Keeps Overweight Rating on Certara, Lifts Price Target to $12

KeyBanc reiterated its Overweight rating on Certara and raised its price target to $12. The move reflects the analyst's updated view on the stock.

TD Cowen Keeps Buy Rating on Certara, Lifts Price Target to $11

TD Cowen reiterated its Buy rating on Certara and raised its price target to $11. The analyst update reflects a higher expected value for the shares.

Barclays keeps Equal-Weight on Certara, lifts target to $9

Barclays reiterated an Equal-Weight rating on Certara and raised its price target to $9. The update reflects the firm's latest view on the stock.

HHS starts project to accelerate clinical trials

The Department of Health and Human Services is launching a project aimed at making clinical trials faster. The effort focuses on speeding up how trials are run.

UBS Downgrades Certara to Neutral, Keeps $10 Price Target

UBS lowered its rating on Certara to Neutral from its prior rating while keeping a $10 price target on the shares.

What is the latest news on CERT?

Oct 27, 2026: Certara named a leader in AI predictive toxicology market (Fiscal.ai) · Oct 16, 2026: KeyBanc Keeps Overweight Rating on Certara, Lifts Price Target to $12 (Benzinga) · Oct 13, 2026: TD Cowen Keeps Buy Rating on Certara, Lifts Price Target to $11 (Benzinga)